MMI0 Stock Overview A clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
MEI Pharma, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for MEI Pharma Historical stock prices Current Share Price US$4.20 52 Week High US$11.40 52 Week Low US$3.58 Beta 0.92 1 Month Change 0% 3 Month Change n/a 1 Year Change -63.79% 3 Year Change -93.14% 5 Year Change -93.84% Change since IPO -96.40%
Recent News & Updates
MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025 Nov 26 MEI Pharma, Inc. Announces Management Changes
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data Apr 12
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients Apr 11
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia Mar 26 MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million. Feb 22
See more updates
MEI Pharma, Inc., Annual General Meeting, Jan 30, 2025 Nov 26 MEI Pharma, Inc. Announces Management Changes
MEI Pharma, Inc. Announces Strategic Plan to Leverage Recent Positive Voruciclib and ME-344 Clinical Data Apr 12
MEI Pharma, Inc. Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients Apr 11
MEI Pharma, Inc. Reports Update from Clinical Study Evaluating Oral Cdk9 Inhibitor Voruciclib in Combination with Venetoclax in Patients with Relapsed and Refractory Acute Myeloid Leukemia Mar 26 MEI Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $10.3 million. Feb 22
MEI Pharma Reports Clinical Data on Oral CDK9 Inhibitor Voruciclib At ASH2023 Dec 12
MEI Pharma, Inc., Annual General Meeting, Dec 18, 2023 Nov 09
MEI Pharma, Inc. Declares Special Cash Dividend of Common Stock, Payable on December 6, 2023 Nov 07
MEI Pharma Announces Acceptance of Abstract for Presentation at ASH 2023 Nov 03
MEI Pharma, Inc. Announces Board Changes Nov 02
MEI Pharma, Inc. to Report Fiscal Year 2023 Results on Sep 26, 2023 Sep 22
MEI Pharma, Inc. Announces First Patient Dosed in Clinical Study Evaluating ME-344 Plus Bevacizumab (AVASTIN) in Patients with Previously Treated Metastatic Colorectal Cancer Aug 17
MEI Pharma, Inc. Announces Chief Financial Officer Changes, Effective as of August 1, 2023 Jul 30 MEI Pharma, Inc. Announces Change of CFO, Effective No Later Than September 1, 2023 MEI Pharma, Inc. Announces Executive Changes
Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million. Jun 01
Funicular Fund, LP, managed by Cable Car Capital, LLC, Anson Funds Management LP, Anson Advisors Inc., Anson Management GP LLC, Bruce R. Winson, Amin Nathoo and Moez Kassam submitted a proposal to acquire remaining 85.2% stake in MEI Pharma, Inc. (NasdaqCM:MEIP) for $45.4 million. May 31
MEI Pharma, Inc Announces Update of Ongoing Phase 1 Study Evaluating Oral CDK9 Inhibitor Voruciclib Alone and in Combination with Venetoclax in Patients with Acute Myeloid Leukemia or B-Cell Malignancies May 24
Insufficient new directors Apr 20
Second quarter 2023 earnings released: EPS: US$0.077 (vs US$0.096 loss in 2Q 2022) Feb 10
Insufficient new directors Jan 11 MEI Pharma, Inc. Initiates Realignment of Its Clinical Development Efforts
Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan Nov 19
First quarter 2023 earnings released: US$0.13 loss per share (vs US$0.17 loss in 1Q 2022) Nov 16
MEI Pharma, Inc. Announces Not Stand for Re-Election of Directors Oct 29
MEI Pharma, Inc., Annual General Meeting, Dec 06, 2022 Oct 28
MEI Pharma, Inc. Announces Not Stand for Re-Election of Cheryl L. Cohen as Member of the Board of Directors Oct 08
Mei Pharma Announces Changes to Board of Directors Sep 23
MEI Pharma, Inc. Announces Board Changes Sep 16
Full year 2022 earnings released: US$0.44 loss per share (vs US$0.37 loss in FY 2021) Sep 10
MEI Pharma, Inc. to Report Fiscal Year 2022 Results on Sep 08, 2022 Sep 02
MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy Jul 19
MEI Pharma Appoints Human Resources Executive Anne Frese as Chief People Officer Jun 23
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 Jun 07
MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022 Jun 06
MEI Pharma, Inc. announced delayed 10-Q filing May 18
MEI Pharma Receives Non-Compliance Notice from Nasdaq May 14
Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat Feb 12
MEI Pharma, Inc. Announces New Key Executive Appointments Feb 08
No longer forecast to breakeven Feb 05
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma Dec 01
Independent Non Executive Director Kevan Clemens has left the company Nov 26
First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.019 loss in 1Q 2021) Nov 11
Forecast to breakeven in 2024 Sep 23
Full year 2021 earnings released: US$0.45 loss per share (vs US$0.51 loss in FY 2020) Sep 05
MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma Aug 18
Forecast to breakeven in 2024 Jul 27
Forecast to breakeven in 2024 Jul 01 MEI Pharma, Inc.(NasdaqCM:MEIP) dropped from Russell 3000E Value Index
MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program Jun 10
MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib Jun 08
MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021 May 21
MEI Pharma and Kyowa Kirin to Present Clinical Data from Phase 1b Study of Zandelisib in Combination with Zanubrutinib at the European Hematology Association 2021 Virtual Congress May 13
Third quarter 2021 earnings released: US$0.28 loss per share (vs US$0.041 loss in 3Q 2020) May 08
Independent Non-Executive Director recently sold €83k worth of stock Feb 25
New 90-day high: €3.28 Feb 10
Second quarter 2021 earnings released: US$0.10 loss per share (vs US$0.26 loss in 2Q 2020) Feb 06
Revenue beats expectations Feb 06
New 90-day high: €2.52 Jan 21
MEI Pharma, Inc. Announces Expansion of Phase 1b Study Evaluating Zandelisib and Clinical Pipeline Update Jan 05
New 90-day low: €2.12 Dec 31
Revenue beats expectations Nov 11
First quarter 2021 earnings released: US$0.019 loss per share Nov 11
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against MEI Pharma, Inc Oct 08
Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce First Patient Dosed in Japanese Pivotal Phase 2 Study of Zandelisib in Patients with Indolent B-Cell Non-Hodgkin's Lymphoma Oct 03
Faruqi & Faruqi, LLP Reminds Investors of Lead Plaintiff Deadline in Class Action Lawsuit Filed Against MEI Pharma, Inc Sep 26
MEI Pharma, Inc. Appoints Brian T. Powl as Senior Vice President, Marketing Sep 16
Full year earnings released - €0.51 loss per share Sep 11
New 90-day low - €2.08 Sep 05
MEI Pharma, Inc. to Report Fiscal Year 2020 Results on Sep 09, 2020 Sep 03
New 90-day low - €2.34 Jul 30 Shareholder Returns MMI0 DE Biotechs DE Market 7D 0% 1.2% -0.3% 1Y -63.8% -14.3% 7.0%
See full shareholder returns
Return vs Market: MMI0 underperformed the German Market which returned 5.9% over the past year.
Price Volatility Is MMI0's price volatile compared to industry and market? MMI0 volatility MMI0 Average Weekly Movement n/a Biotechs Industry Average Movement 7.0% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.6% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: MMI0 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine MMI0's volatility change over the past year.
About the Company MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome.
Show more MEI Pharma, Inc. Fundamentals Summary How do MEI Pharma's earnings and revenue compare to its market cap? MMI0 fundamental statistics Market cap €44.15m Earnings (TTM ) -€33.73m Revenue (TTM ) €52.34m
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) MMI0 income statement (TTM ) Revenue US$58.77m Cost of Revenue US$0 Gross Profit US$58.77m Other Expenses US$96.65m Earnings -US$37.87m
Last Reported Earnings
Mar 31, 2023
Earnings per share (EPS) -5.68 Gross Margin 100.00% Net Profit Margin -64.44% Debt/Equity Ratio 0%
How did MMI0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2023/07/16 16:18 End of Day Share Price 2023/04/18 00:00 Earnings 2023/03/31 Annual Earnings 2022/06/30
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources MEI Pharma, Inc. is covered by 14 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Stephen V. Byrne BofA Global Research Jonathan Aschoff Brean Capital Gene Mack Brean Capital
Show 11 more analysts 
